Results 171 to 180 of about 29,286 (231)

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity. [PDF]

Cancer Immunol Immunother
Lin JR, Song YC, Chou YL, Chen YJ, Hsiao C, Li JP, Ho YJ, Liao WC, Yen HR, Liu CH.   +9 more
europepmc   +1 more source

Mechanisms, Clinical Phenotype and Potential Risk Prediction for Cardiovascular Toxicity Induced by Tyrosine Kinase Inhibitors In Chronic Myeloid Leukemia. [PDF]

Dose Response
Zheng H, Huang C, Zhang Z, Su M, Jiang P, Wu G.   +5 more
europepmc   +1 more source

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia. [PDF]

Leukemia
Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H.   +9 more
europepmc   +1 more source

Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study. [PDF]

BMC Cancer
Cheng F, Wang F, Cui Z, Li Q, Zhu Y, Li W.   +5 more
europepmc   +1 more source

Development and Validation of a Robust RP-HPLC Method for Quantifying Dasatinib in Self-Microemulsifying Drug Delivery Systems. [PDF]

Int J Anal Chem
Kokare NV, Shah RR, Al-Rashidi RSS, Das K, Asdaq SMB, Alsanie WF, Alamri AS, Alhomrani M, Alshammary AF, Hussain SA, Rabbani SI, Bylappa H, Alshehri S.   +12 more
europepmc   +1 more source

Ex Vivo Characterization Studies Identify Candidate Therapies for the Individualized Care of <i>NF2</i>-Related Schwannomatosis. [PDF]

Cancers (Basel)
Hass EW, Nagel A, Scott AJ, Allaway R, Hardin HM, Hayes HM, Huelbes L, Sutton AW, Oliveira SA, Pei M, Telischi FF, Ragheb J, McKinnon M, Khatib Z, Bauer M, Dinh CT, Fernandez-Valle C.   +16 more
europepmc   +1 more source

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Blood
Döhner H, Späth D, Saadati M, Fiedler W, Götze K, Koller E, Westermann J, Vogel W, Heuser M, Lübbert M, Tischler HJ, Germing U, Teichmann LL, Fransecky L, Wölfler A, Nachbaur D, Hertenstein B, Schroers R, Martens U, von Harsdorf S, Radsak M, Aschauer G, Weißhaar S, Corbacioglu A, Schrade A, Gaidzik VI, Thol F, Paschka P, Bullinger L, Benner A, Döhner K, Ganser A.   +31 more
europepmc   +1 more source

Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. [PDF]

Circulation
Jambon-Barbara C, Suissa S, Dell'Aniello S, Hlavaty A, Cracowski JL, Chaumais MC, Humbert M, Montani D, Khouri C.   +8 more
europepmc   +1 more source

Unmasking Cytomegalovirus Colitis: A Case of Haemorrhagic Colitis in a Patient with Chronic Myeloid Leukaemia on Dasatinib. [PDF]

Eur J Case Rep Intern Med
Tole MC, Guevara NA, Sangam S, Mekonen Y, Kushnir Y, Torijano A, Fulger I.   +6 more
europepmc   +1 more source

Adherence to oral antineoplastic agents, an overview and meta-analysis. [PDF]

Oncologist
Mourath D, Fohlin H.
europepmc   +1 more source